Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential P1101 and P1801 in Advanced Solid Tumors
NCT07053904Phase 1Enrolling by invitation
- Sponsor
- PharmaEssentia
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of P1801 in solid tumor (advanced stage), renal cell carcinoma (RCC) and colorectal cancer (CRC) (5 arms), sponsored by PharmaEssentia. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose of P1801 at 28 days. Started Apr 2025; status: enrolling by invitation.
02
Drugs
P1801
03
Conditions
solid tumor (advanced stage)renal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07053904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053904.